[go: up one dir, main page]

WO2018005444A3 - Methods for treating cancer - Google Patents

Methods for treating cancer Download PDF

Info

Publication number
WO2018005444A3
WO2018005444A3 PCT/US2017/039430 US2017039430W WO2018005444A3 WO 2018005444 A3 WO2018005444 A3 WO 2018005444A3 US 2017039430 W US2017039430 W US 2017039430W WO 2018005444 A3 WO2018005444 A3 WO 2018005444A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
foregoing
treating cancer
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/039430
Other languages
French (fr)
Other versions
WO2018005444A2 (en
Inventor
Chiang Jia Li
Matthew HITRON
Youzhi Li
Wei Li
Waldo ORTUZAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Oncology Inc
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Priority to CA3029596A priority Critical patent/CA3029596A1/en
Priority to JP2018568329A priority patent/JP2019519573A/en
Publication of WO2018005444A2 publication Critical patent/WO2018005444A2/en
Publication of WO2018005444A3 publication Critical patent/WO2018005444A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods comprising administering and kits comprising a therapeutically effective amount of at least one first compound chosen from compounds having Formula A: and compounds having Formula B: prodrugs thereof, derivatives thereof, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing; and a therapeutically effective amount of at least one second compound chosen from compounds having Formula C: prodrugs thereof, derivatives thereof, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.
PCT/US2017/039430 2016-06-28 2017-06-27 Methods for treating cancer Ceased WO2018005444A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3029596A CA3029596A1 (en) 2016-06-28 2017-06-27 Methods for treating cancer
JP2018568329A JP2019519573A (en) 2016-06-28 2017-06-27 Methods for treating cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662355410P 2016-06-28 2016-06-28
US62/355,410 2016-06-28
US201762506929P 2017-05-16 2017-05-16
US62/506,929 2017-05-16
US201762514059P 2017-06-02 2017-06-02
US62/514,059 2017-06-02

Publications (2)

Publication Number Publication Date
WO2018005444A2 WO2018005444A2 (en) 2018-01-04
WO2018005444A3 true WO2018005444A3 (en) 2018-02-15

Family

ID=59325662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/039430 Ceased WO2018005444A2 (en) 2016-06-28 2017-06-27 Methods for treating cancer

Country Status (4)

Country Link
JP (1) JP2019519573A (en)
CA (1) CA3029596A1 (en)
TW (1) TW201806592A (en)
WO (1) WO2018005444A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178605A1 (en) * 2018-03-16 2019-09-19 The Board Of Trustees Of The Leland Stanford Junior University Analysis of response to therapeutics in cancer
WO2020061232A1 (en) 2018-09-18 2020-03-26 1 Globe Biomedical Co., Ltd. Treatment for non-alcoholic fatty liver disease
AU2019343922B2 (en) 2018-09-18 2024-01-25 1Globe Biomedical Co., Ltd. Treatment for obesity
US12390153B2 (en) 2019-04-16 2025-08-19 Washington University Ultrasound-target-shape-guided sparse regularization to improve accuracy of diffused optical tomography
CN119318634A (en) * 2023-07-17 2025-01-17 山东大学 BBI 608-entrapped nanoparticle and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2016176190A1 (en) * 2015-04-27 2016-11-03 Boston Biomedical, Inc. Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537639A (en) 2007-08-27 2010-12-09 ボストン バイオメディカル， インコーポレイテッド Asymmetric interfering RNA compositions and uses thereof
CA2736177A1 (en) 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
MX370721B (en) 2010-03-19 2019-12-20 Boston Biomedical Inc Star Novel compounds and compositions for targeting cancer stem cells.
RU2591823C2 (en) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Novel methods for targeting cancer stem cells
WO2012119265A1 (en) 2011-03-04 2012-09-13 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
AU2014243869A1 (en) 2013-03-13 2015-09-24 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
KR20150139955A (en) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 2-acetylnaphtho[2,3-b]furan-4,9-dione for use on treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2016176190A1 (en) * 2015-04-27 2016-11-03 Boston Biomedical, Inc. Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDRE LUIZ MENCALHA ET AL: "LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 65, no. 6, 23 August 2009 (2009-08-23), pages 1039 - 1046, XP019800774, ISSN: 1432-0843 *
ANONYMOUS: "Meeting Library | BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).", 3 June 2017 (2017-06-03), XP055414246, Retrieved from the Internet <URL:http://meetinglibrary.asco.org/record/147826/abstract> [retrieved on 20171010] *
ANONYMOUS: "NCT02279719 on 2016_06_27: ClinicalTrials.gov Archive", 27 June 2016 (2016-06-27), XP055414262, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02279719/2016_06_27> [retrieved on 20171010] *
DONG-XIAN GUAN ET AL: "Sorafenib Enriches Epithelial Cell Adhesion Molecule-Positive Tumor Initiating Cells and Exacerbates a Subtype of Hepatocellular Carcinoma Through TSC2-AKT Cascade", SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES CHINESE ACADEMY OF SCIENCES, 24 October 2015 (2015-10-24), pages 2012 - 10002009, XP055414631, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1002/hep.28117/asset/hep28117.pdf?v=1&t=j8mywk8u&s=48ba1616c311b77426bc5bc07516bf2c72a5e282> [retrieved on 20171011], DOI: 10.1002/hep.28117/suppinfo *
LLOVET J M ET AL: "Sorafenib in advanced hepatocellular carcinoma", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM -, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 359, no. 4, 24 July 2008 (2008-07-24), pages 378 - 390, XP009185548, ISSN: 0028-4793, DOI: 10.1056/NEJMOA0708857 *
YOUZHI LI ET AL: "Suppression of cancer relapse and metastasis by inhibiting cancer stemness", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 112, no. 6, 20 January 2015 (2015-01-20), US, pages 1839 - 1844, XP055283316, ISSN: 0027-8424, DOI: 10.1073/pnas.1424171112 *

Also Published As

Publication number Publication date
WO2018005444A2 (en) 2018-01-04
JP2019519573A (en) 2019-07-11
TW201806592A (en) 2018-03-01
CA3029596A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
CY1124652T1 (en) 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL ACTIVITY OF THE COMPLEMENT SYSTEM, SUCH AS E.G. IMMUNOLOGICAL DISORDERS
PH12022551574A1 (en) Egfr inhibitors
PH12021552482A1 (en) Compounds targeting prmt5
ZA202206923B (en) New methylquinazolinone derivatives
WO2018086591A8 (en) Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
EP4442695A3 (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
SA520411524B1 (en) Bisamide sarcomere activating compounds and uses thereof
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2021014531A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith.
WO2018005444A3 (en) Methods for treating cancer
IL290177A (en) 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
WO2017067530A3 (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
PH12021552513A1 (en) Pyrrole compounds
MX2021007247A (en) Rapamycin derivatives.
MX2022007626A (en) COMBINATIONS.
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
MX2022007628A (en) Combinations.
MX2021007258A (en) Amorphous sparsentan compositions.
PH12021552953A1 (en) Tricyclic compounds
NZ790037A (en) Combinations
WO2018039077A8 (en) Therapeutic compounds
WO2017095950A3 (en) Compounds for treating proliferative diseases
MX379576B (en) AZETIDINE DERIVATIVES
WO2015127284A3 (en) Antimitotic amides for the treatment of cancer and proliferative disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17739417

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018568329

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3029596

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17739417

Country of ref document: EP

Kind code of ref document: A2